Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00782600 · ClinicalTrials.gov registry record · Phase 1
Study of Controlled Release Formulations of CE-224,535 Against the Immediate Release Formulation in Normal Volunteers
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT00782600 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 16 participants.
The verdict
NCT00782600, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
This study is to test the idea that a controlled release formulation of CE-224,535 may allow for less frequent dosing and exposure to lower levels of drug than an immediate release formulation.
Interventions
- DRUG suspension IR
- DRUG CR 1
- DRUG CR 2
- DRUG CR 3
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2008-07 |
| Est. Completion | 2008-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00782600
The ClinicalTrials.gov registry entry for NCT00782600 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which suspension IR is the first listed.
NCT00782600 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00782600 about?
NCT00782600 is a clinical study titled "Study of Controlled Release Formulations of CE-224,535 Against the Immediate Release Formulation in Normal Volunteers". This study is to test the idea that a controlled release formulation of CE-224,535 may allow for less frequent dosing and exposure to lower levels of drug than an immediate release formulation.
What is the current status of trial NCT00782600?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2008-07. Estimated completion is 2008-08.
What interventions are being tested in trial NCT00782600?
The interventions under investigation include: suspension IR (DRUG), CR 1 (DRUG), CR 2 (DRUG), CR 3 (DRUG).
Who is sponsoring clinical trial NCT00782600?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.